½ÃÀ庸°í¼­
»óǰÄÚµå
1735877

¼¼°èÀÇ ¸»ÃÊÇ÷°ü ±â±â ¾÷°è(2024-2029³â)

Peripheral Vascular Devices Industry, Global, 2024-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 54 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾à¹° ¿ëÃâ ½ºÅÙÆ® ¹× ¾à¹° ÄÚÆÃ Ç³¼± Çõ½ÅÀ¸·Î Çõ½ÅÀû ¼ºÀå ÃËÁø

Frost & SullivanÀº ¿¹Ãø ±â°£ µ¿¾È ¾à¹° ¿ëÃâ ½ºÅÙÆ® ¹× ¾à¹° ÄÚÆÃ Ç³¼±À¸·ÎÀÇ ÀüȯÀÌ ¸»ÃÊÇ÷°ü ÀåÄ¡ »ê¾÷À» À̲ô´Â ÁÖ¿ä Æ®·»µå°¡ µÉ °ÍÀ¸·Î º¸°í ÀÖ½À´Ï´Ù. »ýÈí¼ö¼º ½ºÄ³Æúµå¿¡ ´ëÇÑ ÅõÀÚ°¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¾à¹° ¿ëÃ⼺ »ýÈí¼ö¼º ½ºÄ³Æúµå´Â ¾÷°è °ü°èÀÚµé »çÀÌ¿¡¼­ °ü½ÉÀÌ ³ôÀº ºÐ¾ßÀÔ´Ï´Ù. ¶ÇÇÑ, ¸»Ãʵ¿¸ÆÁúȯ, ƯÈ÷ ¹«¸­ ¾Æ·¡ ¸»Ãʵ¿¸ÆÁúȯ°ú »çÁö Àý´ÜÀ¸·Î À̾îÁú ¼ö ÀÖ´Â ¸¸¼º ÇãÇ÷¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç °³¹ß¿¡ ´ëÇÑ °ü½ÉÀº ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±Ý¼Ó ½ºÅÙÆ®, »ýüÈí¼ö¼º ½ºÅÙÆ®, ¾à¹° ¿ëÃâ ½ºÅÙÆ®, ¾à¹° ÄÚÆÃ Ç³¼±, °æÇÇÀû °æ°ü Ç÷°ü¼ºÇü¼ú(PTA) dz¼±, Ä«Å×ÅÍ µî ¸»ÃÊÇ÷°ü ±â±â¸¦ ºÐ¼®ÇÕ´Ï´Ù. ºÐ¼® Áö¿ªÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ³ª´µ¾îÁ® ÀÖ½À´Ï´Ù. »ê¾÷ ±Ô¸ð, ¼ºÀå·ü, ¼ºÀå ±âȸ, Àü·«Àû °úÁ¦, ȯÀÚ °æ·Î, ±â¾÷ ½ÃÀå Á¡À¯À², ½Ã¼ú µ¿Çâ, ½Å±â¼ú, ÃÖÁ¾»ç¿ëÀÚ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

Á¶»ç±â°£Àº 2021³âºÎÅÍ 2029³â±îÁö, ±âÁØ ¿¬µµ´Â 2024³â, ¿¹Ãø ±â°£Àº 2024³âºÎÅÍ 2029³â±îÁöÀÔ´Ï´Ù.

¸ñÂ÷

Á¶»ç ¹üÀ§

  • ºÐ¼® ¹üÀ§
  • ¼¼ºÐÈ­

¼ºÀå ȯ°æ : ¸»ÃÊÇ÷°ü ±â±â ¾÷°èÀÇ Àüȯ

  • ¿Ö ¼ºÀåÀÌ ¾î·Á¿öÁö´Â°¡?
  • The Strategic Imperative 8
  • ¸»ÃÊÇ÷°ü ±â±â ¾÷°è¿¡ ´ëÇÑ 3´ë Àü·«Àû ¿øÄ¢ÀÇ ¿µÇâ

¸»ÃÊÇ÷°ü ±â±â ¾÷°èÀÇ »ýŰè

  • °æÀï ȯ°æ
  • ÁÖ¿ä °æÀï»ç

¸»ÃÊÇ÷°ü ±â±â ¾÷°èÀÇ ¼ºÀå Á¦³Ê·¹ÀÌÅÍ

  • ÁÖ¿ä µ¿Çâ, 2024³â
  • ¼ºÀå ÁöÇ¥
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ¿¹Ãø ÀλçÀÌÆ®
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç°º° ¸ÅÃâ ¿¹Ãø
  • Áö¿ªº° ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø ºÐ¼®
  • °¡°Ý µ¿Çâ°ú ¿¹Ãø ºÐ¼®
  • ¸»ÃÊÇ÷°ü ±â±â
  • ¸ÅÃâ Á¡À¯À²
  • ¸ÅÃâ Á¡À¯À² ºÐ¼®
  • ÁÖ¸ñÇÒ ¸¸ÇÑ ±â¾÷ : Æ÷Æ®Æú¸®¿À
  • ȯÀÚ °æ·Î : ¸»ÃÊÇ÷°ü ÀÎÅͺ¥¼Ç
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ¸»ÃÊÇ÷°ü Áúȯ¿ë »õ·Î¿î ¼Ö·ç¼Ç
  • ¸»ÃÊÇ÷°ü ÀÎÅͺ¥¼ÇÀÇ ·Îº¿

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ºÏ¹Ì

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç°º° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®
  • ¸»ÃÊÇ÷°ü ÀÎÅͺ¥¼Ç ½Ã¼ú µ¿Çâ

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : À¯·´

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç°º° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ¾Æ½Ã¾ÆÅÂÆò¾ç

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç°º° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : ¶óƾ¾Æ¸Þ¸®Ä«

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç°º° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

¼ºÀå Á¦³Ê·¹ÀÌÅÍ : Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • Á¦Ç°º° ¸ÅÃâ ¿¹Ãø
  • ¿¹Ãø ºÐ¼®

¸»ÃÊÇ÷°ü ±â±â ¾÷°èÀÇ ¼ºÀå ±âȸ À¯´Ï¹ö½º

  • ¼ºÀå ±âȸ 1 : ½½ÇÏ ¸»Ãʵ¿¸ÆÁúȯ¿ë »ýüÈí¼ö¼º ½ºÄ³Æúµå °³·®
  • ¼ºÀå ±âȸ 2 : »çÁö ¸¶ºñ¸¦ ÃÊ·¡ÇÏ´Â ¸¸¼ºÇãÇ÷(CLTI)¿¡ ´ëÇÑ ¾à¹° ¿ëÃâ ¼Ö·ç¼Ç °³¹ß
  • ¼ºÀå ±âȸ 3 : Áß±¹°ú Àεµ·ÎÀÇ ÁøÃâ
  • ¼ºÀå ±âȸ 4 : ¿Ü·¡ Áø·á¿¡ ´ëÇÑ ÁÖ·Â
  • ¼ºÀå ±âȸ 5 : ¸»Ãʵ¿¸ÆÁúȯ ½ºÅ©¸®´×°ú ¸ð´ÏÅ͸µ ÀÎÁöµµ Çâ»ó

ºÎ·Ï°ú ´ÙÀ½ ´Ü°è

  • ¼ºÀå ±âȸÀÇ ÀÌÀͰú ¿µÇâ
  • ´ÙÀ½ ´Ü°è
  • ÷ºÎ ¸®½ºÆ®
  • ¸éÃ¥»çÇ×
ksm 25.06.16

Innovations in Drug-eluting Stents and Drug-coated Balloons are Driving Transformational Growth

Frost & Sullivan observes that the shift to drug-eluting stents and drug-coated balloons will be the key trends driving the peripheral vascular devices industry during the forecast period. Investments in bioresorbable scaffolds will further drive the market growth. Drug-eluting bioresorbable scaffolds are an area of interest among industry stakeholders. Moreover, interest in developing innovative solutions for peripheral artery disease, especially below-the-knee peripheral artery disease and complex chronic limb-threatening ischemia, positively impacts the market growth.

This study analyzes peripheral vascular devices, such as metal stents, bioresorbable stents, drug-eluting stents, drug-coated balloons, percutaneous transluminal angioplasty (PTA) balloons, and catheters. Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The study provides insights into industry size, growth rates, growth opportunities, strategic imperatives, patient pathways, company market share, procedure trends, new technologies, and end users.

The study period is from 2021 to 2029, the base year is 2024, and the forecast period is from 2024 to 2029.

Table of Contents

Research Scope

  • Scope of Analysis
  • Segmentation

Growth Environment: Transformation in the Peripheral Vascular Devices Industry

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8
  • The Impact of the Top 3 Strategic Imperatives on the Peripheral Vascular Devices Industry

Ecosystem in the Peripheral Vascular Devices Industry

  • Competitive Environment
  • Key Competitors

Growth Generator in the Peripheral Vascular Devices Industry

  • Top Trends in 2024
  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Forecast Considerations
  • Revenue Forecast
  • Revenue Forecast by Product
  • Revenue Forecast by Region
  • Revenue Forecast Analysis
  • Pricing Trends and Forecast Analysis
  • Peripheral Vascular Devices
  • Revenue Share
  • Revenue Share Analysis
  • Notable Players: Portfolio
  • Patient Pathway: Peripheral Interventions
  • End User Analysis
  • New Solutions for Peripheral Vascular Disease
  • Robotics in Peripheral Interventions

Growth Generator: North America

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product
  • Forecast Analysis
  • Peripheral Interventional Procedure Trends

Growth Generator: Europe

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product
  • Forecast Analysis

Growth Generator: Asia-Pacific

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product
  • Forecast Analysis

Growth Generator: Latin America

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product
  • Forecast Analysis

Growth Generator: Middle East and Africa

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Product
  • Forecast Analysis

Growth Opportunity Universe in the Peripheral Vascular Devices Industry

  • Growth Opportunity 1: Improve Bioresorbable Scaffolds for Below-the-knee Peripheral Artery Disease
  • Growth Opportunity 2: Develop Drug-eluting Solutions for Chronic Limb-threatening Ischaemia CLTI
  • Growth Opportunity 3: Expand into China and India
  • Growth Opportunity 4: Focus on Outpatient Settings
  • Growth Opportunity 5: Increase Awareness of Peripheral Artery Disease Screening and Monitoring

Appendix & Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • List of Exhibits
  • Legal Disclaimer
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦